IP Library Granted Patent US 8,926,991
Granted Patent B2
US 8,926,991 · App. 11/447,984 · Granted Jan 6, 2015

Botulinum toxin and the treatment of primary disorders of mood and affect

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,926,991
App. No.
11/447,984
Granted
Jan 6, 2015
Kind
B2
Abstract

The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.

Claims (23)

1. A method of treating sleep onset insomnia or sleep maintenance insomnia comprising the steps of:

a) identifying a subject with said sleep disorder; and

b) administering an effective amount of a composition comprising a botulinum toxin immunotype A and a pharmaceutically acceptable carrier to said subject thereby reducing at least one symptom of said sleep disorder.

2. The method of claim 1 , wherein the botulinum toxin is botulinum toxin type A from Hall strain Clostridium botulinum.

3. The method of claim 1 , wherein the composition is administered by injection.

4. The method of claim 3 , wherein the injection is multifocal.

5. The method of claim 3 , wherein the composition is administered to the forehead.

6. The method of claim 3 , wherein the composition is administered to the scalp.

7. The method of claim 3 , wherein the composition is administered to the neck.

8. The method of claim 1 , wherein there are at least two injection sites.

9. The method of claim 1 , wherein the composition is administered transdermally.

10. A method of treating sleep onset insomnia or sleep maintenance insomnia comprising the steps of:

a) identifying a subject with said sleep disorder;

b) administering to said subject a composition comprising a botulinum toxin immunotype A and a pharmaceutically acceptable carrier by injection.

11. The method of claim 10 , wherein said composition decreases choline acetyltransferase activity.

12. The method of claim 10 , wherein said composition decreases synthesis of acetylcholine.

13. The method of claim 10 , wherein said botulinum toxin immunotype A is of the Hall strain.

14. The method of claim 10 , wherein injection is transcutaneous, subcutaneous, transdermal, or intramuscular.

15. The method of claim 14 , wherein the injection is multifocal.

16. The method of claim 14 , wherein the composition is administered to the brow or forehead.

17. The method of claim 14 , wherein the composition is administered to the scalp.

18. The method of claim 14 , wherein the composition is administered to the neck.

19. The method of claim 10 , wherein the composition is administered transdermally.

Assignments (7)
SECURITY INTEREST Recorded Feb 17, 2025
From: REVANCE THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 070239/0739 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2025
From: ATHYRIUM BUFFALO LP
To: REVANCE THERAPEUTICS, INC
Reel/Frame 070153/0630 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0663 →
SECURITY INTEREST Recorded Feb 7, 2025
From: REVANCE THERAPEUTICS, INC.; BELLUS MEDICAL, LLC; CROWN LABORATORIES, INC.
To: HAYFIN SERVICES LLP, AS ADMINISTRATIVE AGENT
Reel/Frame 070153/0736 →
SECURITY INTEREST Recorded Mar 18, 2022
From: REVANCE THERAPEUTICS, INC.
To: ATHYRIUM BUFFALO LP
Reel/Frame 059437/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2016
From: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 038870/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2010
From: BORODIC, GARY E.
To: BOTULINUM TOXIN RESEARCH ASSOCIATES, INC.
Reel/Frame 023875/0904 →